Aspira Pathlab & Diagnostics Ltd () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 1002885, "name": "Aspira Pathlab", "stock_name": "Aspira Pathlab", "full_name": "Aspira Pathlab & Diagnostics Ltd", "name_url": "stocks-analysis/aspira-pathlab", "exchange": 0, "exchangecode": "", "primexch": 0, "country_id": 34, "currency": "INR", "cmp": "59.35", "chg": 1.15, "chgp": "1.98%", "dir": 1, "prev_price": "58.20", "mcapval": "62.00 Cr", "mcap": "Micro Cap", "scripcode": 540788, "symbol": "", "ind_name": "Healthcare Services", "ind_code": 94, "indexname": "India SENSEX", "isin": "INE500C01017", "curr_date": "Apr 17", "curr_time": "", "bse_nse_vol": 673, "exc_status": "Active", "traded_date": "Apr 17, 2026", "traded_date_str": "2026 04 17", "score": "", "scoreText": "", "Live": 0, "market_time": 0, "is_blur": 1, "is_blur_class": "blur-registerF-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/aspira-pathlab-1002885-0&utm_source=Spage_Header_Score", "mojoone": { "ismore": 0 } }, "news": { "results": [ { "title": "Aspira Pathlab & Diagnostics Ltd Falls to 52-Week Low of Rs 49 as Sell-Off Deepens", "link": "https://www.marketsmojo.com/news/stocks-in-action/aspira-pathlab-diagnostics-ltd-falls-to-52-week-low-of-rs49-3947617", "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/AspiraPathlabDi_priceRelatedfactors_3947617.png", "date": "2026-04-15 12:10:15", "description": "A sharp decline in Aspira Pathlab & Diagnostics Ltd has pushed the stock to a fresh 52-week low of Rs 49 on 15 Apr 2026, marking a significant 39.5% drop from its 52-week high of Rs 81. This comes amid heightened volatility and a continuation of recent losses, despite some contrasting financial signals." }, { "title": "Aspira Pathlab & Diagnostics Ltd is Rated Strong Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/aspira-pathlab-diagnostics-ltd-is-rated-strong-sell-3941524", "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/AspiraPathlabDi_mojoScore_3941524.png", "date": "2026-04-10 10:10:24", "description": "Aspira Pathlab & Diagnostics Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 13 Feb 2026, reflecting a significant reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed below are current as of 10 April 2026, providing investors with an up-to-date view of the company’s position." }, { "title": "Aspira Pathlab & Diagnostics Ltd is Rated Strong Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/aspira-pathlab-amp-diagnostics-ltd-is-rated-strong-sell-3923830", "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/AspiraPathlabDi_mojoScore_3923830.png", "date": "2026-03-30 10:10:17", "description": "Aspira Pathlab & Diagnostics Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 13 February 2026, reflecting a shift from the previous 'Sell' grade. However, the analysis and financial metrics discussed here represent the company’s current position as of 30 March 2026, providing investors with the latest insights into its performance and outlook." }, { "title": "Aspira Pathlab & Diagnostics Ltd is Rated Strong Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/aspira-pathlab-amp-diagnostics-ltd-is-rated-strong-sell-3893330", "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/AspiraPathlabDi_mojoScore_3893330.png", "date": "2026-03-16 10:10:02", "description": "Aspira Pathlab & Diagnostics Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 13 February 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 16 March 2026, providing investors with the most up-to-date view of the company’s performance and outlook." }, { "title": "Aspira Pathlab & Diagnostics Ltd is Rated Strong Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/aspira-pathlab-amp-diagnostics-ltd-is-rated-strong-sell-3873246", "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/AspiraPathlabDi_mojoScore_3873246.png", "date": "2026-03-05 10:10:02", "description": "Aspira Pathlab & Diagnostics Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 13 February 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 05 March 2026, providing investors with the latest insights into the company’s performance and outlook." }, { "title": "Aspira Pathlab & Diagnostics Downgraded to Strong Sell Amid Financial and Technical Weakness", "link": "https://www.marketsmojo.com/news/stock-recommendation/aspira-pathlab-diagnostics-downgraded-to-strong-sell-amid-financial-and-technical-weakness-3841909", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/AspiraPathlabDi_mojoScore_3841909.png", "date": "2026-02-16 08:38:03", "description": "Aspira Pathlab & Diagnostics Ltd has been downgraded from a Sell to a Strong Sell rating following a comprehensive reassessment of its financial performance, valuation metrics, technical indicators, and overall quality. The downgrade reflects significant deterioration in quarterly earnings, a shift in technical trends, and a reassessment of valuation attractiveness, signalling heightened caution for investors in the healthcare services sector." }, { "title": "Aspira Pathlab Falls 9.45%: 3 Key Factors Driving the Weekly Decline", "link": "https://www.marketsmojo.com/news/stocks-in-action/aspira-pathlab-falls-945-3-key-factors-driving-the-weekly-decline-3839359", "imagepath": "", "date": "2026-02-14 12:01:06", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>9 Feb:</strong> Stock opens at ₹67.99, up 1.67% on positive technical upgrade</p>\n <p><strong>10 Feb:</strong> Mojo Grade upgraded to Hold by MarketsMOJO</p>\n <p><strong>11 Feb:</strong> Q1 FY26 results reveal profitability surge but operational challenges</p>\n <p><strong>12 Feb:</strong> Valuation grade downgraded amid sharp price decline</p>\n <p><strong>13 Feb:</strong> Week closes at ₹60.55, down 1.26% on final trading day</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">₹66.87</d..." }, { "title": "Aspira Pathlab & Diagnostics Ltd: Valuation Shift Signals Changing Market Sentiment", "link": "https://www.marketsmojo.com/news/stocks-in-action/aspira-pathlab-diagnostics-ltd-valuation-shift-signals-changing-market-sentiment-3834324", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/AspiraPathlabDi_valuationdot_3834324.png", "date": "2026-02-12 08:04:53", "description": "Aspira Pathlab & Diagnostics Ltd has experienced a notable shift in its valuation parameters, moving from a very attractive to an attractive rating. This change reflects evolving market perceptions amid fluctuating price-to-earnings (P/E) and price-to-book value (P/BV) ratios, alongside peer comparisons and historical benchmarks. Investors are now reassessing the stock’s price attractiveness within the healthcare services sector, as the company’s financial metrics and market performance reveal a complex picture." }, { "title": "Aspira Pathlab Q1 FY26: Profitability Surge Masks Underlying Operational Challenges", "link": "https://www.marketsmojo.com/news/result-analysis/aspira-pathlab-q1-fy26-profitability-surge-masks-underlying-operational-challenges-3832988", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/AspiraPathlabDi_quaterlyResult_3832988.png", "date": "2026-02-11 09:47:53", "description": "Aspira Pathlab & Diagnostics Ltd., a Mumbai-based pathology specialist with pan-India presence, reported a dramatic turnaround in profitability for Q1 FY26, posting a consolidated net profit of ₹0.42 crores compared to a loss of ₹0.01 crores in Q1 FY25—marking an impressive 740.00% year-on-year growth. However, the quarter-on-quarter trajectory reveals a more concerning narrative, with net profit declining 38.24% from ₹0.68 crores in Q4 FY25, whilst the stock retreated 5.88% in recent trading to close at ₹64.00, reflecting investor caution about the company's near-term prospects." } ], "total": 6140, "sid": "1002885", "stock_news_url": "https://www.marketsmojo.com/news/aspira-pathlab-diagnostics-1002885" }, "announcements": [ { "caption": "Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A", "datetime": "15-Apr-2026", "details": "<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Aspira Pathlab & Diagnostics Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L85100MH1973PLC289209</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>0</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: Company is under the process to appoint Company Secretary <br/> Designation: Company Secretary <br/> EmailId: info@aspiradiagnostics.com</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: Balkrishna Talawadekar <br/> Designation: Chief Financial Officer <br/> EmailId: balkrishna.talawadekar@aspiradiagnostics.com</div> </div> <div> <br/> Date: 15/04/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>", "source": "BSE" }, { "caption": "Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2", "datetime": "15-Apr-2026", "details": "<b>Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px> <tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr> <td>1</td> <td>Name of Company</td> <td>Aspira Pathlab & Diagnostics Ltd</td> </tr> <tr> <td>2</td> <td>CIN NO.</td> <td>L85100MH1973PLC289209</td> </tr> <tr> <td>3</td> <td>Report filed for FY</td> <td>2025-2026</td> </tr> <tr><td colspan=3>Details of the Current block (all figures in Rs crore):</td><tr> <tr> <td>4</td> <td>2 - year block period (Specify financial years)* </td> <td>NA</td> </tr> <tr> <tr> <td>5</td> <td>Incremental borrowing done in FY (T)(a) </td> <td>0.00</td> </tr> <tr> <td>6</td> <td>Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a)</td> <td>0.00</td> </tr> <tr> <td>7</td> <td>Actual borrowing done through debt securities in FY (T)(c)</td> <td>0.00</td> </tr> <tr> <td>8</td> <td> Shortfall in the borrowing through debt securities if any for FY (T - 1) carried forward to FY (T) (d)</td> <td>0</td> </tr> <tr> <td>8</td><td>Quantum of (d) which has been met from (c)(e)*</td> <td>0</td> </tr><tr> <td>9</td><td> Shortfall if any in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative write nil}*</td> <td>0</td> </tr> </table> <br/><br/><table><tr><td colspan=2><b>Details of penalty to be paid if any in respect to previous block (all figures in Rs crore):</b></td></tr> <tr><td>2 - year Block period (Specify financial years)</td><td>NA</td></tr> <tr><td>Amount of fine to be paid for the block if applicable Fine = 0.2% of {(d) - (e)}#</td><td>0.00</td></tr> </table> <div> <br/><br/><br/> <table><tr><td>Name of the Company Secretary :-</td><td>Company is under the process to appoint Company Secretary</td></tr><tr><td>Designation :-</td><td>Company Secretary</td></tr> <tr><td>Name of the Chief Financial Officer :- </td><td>Balkrishna Talawadekar </td></tr> <tr><td>Designation : -</td><td>Chief Financial Officer</td></tr></table><div> <br/> Date: 15/04/2026<br/><br/></div>", "source": "BSE" }, { "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018", "datetime": "14-Apr-2026", "details": "Compliance Certificate in accordance with Regulation 74(5) of SEBI (DP) Regulations 2018 For quarter ended 31 March 2026", "source": "BSE" } ], "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "<span>No</span> Upcoming Board Meetings", "data": [] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "No <strong>Dividend</strong> history available", "data": [] }, { "img": "splits.svg", "title": "SPLITS", "msg": "No <strong>Splits</strong> history available", "data": [] }, { "img": "bonus.svg", "title": "BONUS", "msg": "No <strong>Bonus</strong> history available", "data": [] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "No <strong>Rights</strong> history available", "data": [] } ] }

Key Events This Week

9 Feb: Stock opens at ₹67.99, up 1.67% on positive technical upgrade

10 Feb: Mojo Grade upgraded to Hold by MarketsMOJO

11 Feb: Q1 FY26 results reveal profitability surge but operational challenges

12 Feb: Valuation grade downgraded amid sharp price decline

13 Feb: Week closes at ₹60.55, down 1.26% on final trading day

Week Open

₹66.87Read full news article

Aspira Pathlab & Diagnostics Ltd: Valuation Shift Signals Changing Market Sentiment

2026-02-12 08:04:53

Aspira Pathlab & Diagnostics Ltd has experienced a notable shift in its valuation parameters, moving from a very attractive to an attractive rating. This change reflects evolving market perceptions amid fluctuating price-to-earnings (P/E) and price-to-book value (P/BV) ratios, alongside peer comparisons and historical benchmarks. Investors are now reassessing the stock’s price attractiveness within the healthcare services sector, as the company’s financial metrics and market performance reveal a complex picture.

Read full news article

Aspira Pathlab Q1 FY26: Profitability Surge Masks Underlying Operational Challenges

2026-02-11 09:47:53

Aspira Pathlab & Diagnostics Ltd., a Mumbai-based pathology specialist with pan-India presence, reported a dramatic turnaround in profitability for Q1 FY26, posting a consolidated net profit of ₹0.42 crores compared to a loss of ₹0.01 crores in Q1 FY25—marking an impressive 740.00% year-on-year growth. However, the quarter-on-quarter trajectory reveals a more concerning narrative, with net profit declining 38.24% from ₹0.68 crores in Q4 FY25, whilst the stock retreated 5.88% in recent trading to close at ₹64.00, reflecting investor caution about the company's near-term prospects.

Read full news article

Sr. No.	Particulars	Details
1	Name of Company	Aspira Pathlab & Diagnostics Ltd
2	CIN NO.	L85100MH1973PLC289209
3	Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)	0.00
4	Highest Credit Rating during the previous FY	0
4a	Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)	Not Applicable
5	Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework	BSE

Details of penalty to be paid if any in respect to previous block (all figures in Rs crore):
2 - year Block period (Specify financial years)	NA
Amount of fine to be paid for the block if applicable Fine = 0.2% of {(d) - (e)}#	0.00

Name of the Company Secretary :-	Company is under the process to appoint Company Secretary
Designation :-	Company Secretary
Name of the Chief Financial Officer :-	Balkrishna Talawadekar
Designation : -	Chief Financial Officer